Reported by talkSPORT 16 minutes ago.
Haseeb Hameed injury latest: England opener to return from India for operation on injured finger
↧
↧
Kookaburras lose hockey Test 3-2 to India
India have beaten the Kookaburras 3-2 at the Bendigo Hockey Centre in the first of two Tests.
Reported by SBS 18 minutes ago.
↧
SANY's Newly Launched C10 Series Rotary Drilling Rigs Yields Orders of USD15 Million
BEIJING, Nov. 29, 2016 /PRNewswire/ -- On Nov 20, SANY Heavy Machinery, a branch of SANY Heavy Industry, launched the C10 series rotary drilling rigs globally and 16 units worth 15 million USD were ordered during the launching ceremony at SANY's Nankou Industrial Park in Beijing.On Nov 20, SANY Heavy Machinery launched the C10 series rotary drilling rigs, available with a wide range of operating capacities.SANY C10 rotary drilling rigs are available with a wide range of operating capacities, including small and medium size rigs models SR155C10, SR205C10, SR235C10, 265C10 for civil construction, SR285RC10, SR360RC10 and SR365RC10 rotary drilling rigs for rock drilling, SR405RC10 large size rotary drilling rigs, and SR235W10, SR285RW10 full stroke rotary drilling rigs.
The performance of C10 series rotary drilling rig has been enhanced and modified with enlarged pile diameter, extended pile depth, stronger engine power and faster speed line of the main winch. The 5th generation rotary drive with multi-gear control has been adopted to increase the drilling efficiency. New design of the main winch, low fuel consumption and environmental friendly engines from Isuzu or Cummins, unique tailor-made chassis all contribute to their efficient and stable operation.
Moreover, the spacious cab with panorama sunroof is designed to give the operator a more comfortable environment and wider visibility. High strength SANY Kelly bar and auto center lubrication systems ensure a longer service life of the drilling machine.
"We will never stop our pace to create the value for customers, carry out technological innovation as always, provide more cost-effective pilling machines, and the most comprehensive after-sales service to all of you," said Mr. Xiong Yiqun, general manager of SANY Heavy Machinery Beijing branch.
The launch ceremony for the C10 series was also one part of the SANY First Global Dealer Summit, which was held on Nov 20-21, to drive forward the company's international development in cooperation with dealers and partners across the globe.
The dealers who attended the ceremony were impressed by the newly launched C10 series. As one of SANY's main partners overseas, the RTC Company designed a special drilling bar together for the foundation work in northern Russia, with that the optimized rotary drilling rigs are able to start and operate efficiently even at minus 50 Celsius degrees in the Arctic and can be operated for 24 hours without any kind of technical breakdown. Also with SANY's extensive service network, customers are avail of spontaneous technical and spare parts support.
*About SANY Group*
SANY Group (SANY), which has its global headquarter in China, is a world leading heavy machinery manufacturer with plants in the US, Germany, Brazil and India, and business covering over 100 countries and regions worldwide. The company has been recognized as one of the most innovative and successful companies in the world, and its concrete machinery is ranked No. 1 globally.
For more information, please visit: www.sanyglobal.com, or follow SANY Group on Facebook and YouTube.
For more information contact:
Rebecca Zhou
+86-10-6073-7480
zhouyy5@sanygroup.cn
Photo - http://photos.prnasia.com/prnh/20161129/0861612854 Reported by PR Newswire Asia 13 minutes ago.
↧
DRG and Zephyr Health Announce Partnership to Optimize the Commercial and Market Access Experience for Pharma Stakeholders
BURLINGTON, Mass. and SAN FRANCISCO, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Decision Resources Group (DRG) , a leading provider of proprietary data products and solutions to the healthcare industry, and Zephyr Health , the leading Insights-as-a-Service solution provider for life sciences companies, today announced a new strategic data and analytics partnership. The partnership will pair DRG's best-in-class data and information services with Zephyr Health's analytics and insights technology to deliver unique and dynamic market access solutions for commercial teams within the life sciences industry.
Through this collaboration, DRG and Zephyr Health will offer unique solutions that integrate provider, institution and payer data to bring rich, actionable insights to commercial teams. These solutions will enable life sciences sales and account teams to be at the forefront of understanding the most recent changes to payer or formulary status for their target markets and customers.
The partnership's first offering, "Market Access Potential" is a user-centric, analytics suite that leverages the new, advanced capabilities in the Zephyr Illuminate software platform as well as DRG's rich market access data. Market Access Potential will provide users real-time, relevant insights for improved account planning and customer engagement. This new platform will transform how market access data is managed within commercial teams, enabling a sales representative to understand physician access, formulary pull-through, and the increasing role of Integrated Delivery Networks (IDNs) and Accountable Care Organizations (ACOs) in physician decision making. Market Access Potential is currently enrolling charter customers and will be broadly available early in 2017.
Matthew McKnight, COO of DRG, commented, "As the healthcare access and reimbursement environment continues to evolve, DRG's partnership with Zephyr Health empowers life sciences companies by combining Zephyr's innovative software and intuitive design with proprietary data and analytics from DRG to provide a product that dramatically improves the efficiency and effectiveness of sales teams. By combining efforts, DRG and Zephyr Health have created a unique market access and reimbursement solution for the next wave of life science industry drug launches."
"We are excited to be working with DRG, an industry leader in market access data, to optimize how information is consumed by life sciences teams, and develop real-time recommendations for messaging and customer engagement," said Lance Scott, President and CEO, Zephyr Health. "Linking specific health plan information and providing visibility to the formulary and reimbursement status of a company's product at the individual physician level is a game-changer for commercial teams operating in a complicated and dynamic physician access landscape."
*About Decision Resources Group*
Decision Resources Group, a subsidiary of Piramal Enterprises Ltd., offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 1000 employees across 17 global locations. DRG provides the pharmaceutical, biotech, medical device, payer, provider, and financial services industries with the tools, insights and advice they need to compete and thrive in an increasingly complex and value-based marketplace.
DRG's Real World Data (RWD) repository covers over 260 million unique US patients with over five years of historical data. This robust claims data, combined with electronic health records (EHR) detail, allows for comprehensive analyses of in-market patient care, patient cost burden, and trends in patient outcomes. Additionally, DRG's RWD repository, integrated with leading formulary coverage analysis in the US, enables detailed profiling of health care provider prescribing and treatment behavior, and assists pharmaceutical and medical device manufacturers in identifying and eliminating barriers to patient access.
www.DecisionResourcesGroup.com
*About Zephyr Health*
Zephyr Health helps life sciences companies - pharmaceutical, biotech, medical device and diagnostics - engage the right physicians, accounts and institutions using insights from global health data. Zephyr Illuminate (TM) is a leading Insights-as-a-Service solution that integrates thousands of data sources to create precise and predictive insights. From pre-launch to product maturity, life sciences companies can make confident decisions faster with data-driven targeting and deep customer profiles. Zephyr Health's customers include several of the Top 10 Pharmaceutical, Biotech and Medical Device companies.
Zephyr Health is a privately held company headquartered in San Francisco with offices in London, UK, and Pune, India. Zephyr Health is venture backed by Google Ventures, Kleiner Perkins Caufield & Byers and Icon Ventures. For more information, please visit: www.zephyrhealth.com . Media contact for DRG:
Tori McClain
tmcclain@teamdrg.com
Media contact for Zephyr Health:
pr@zephyrhealth.com
--------------------This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zephyr Health via GlobeNewswire
HUG#2059943 Reported by GlobeNewswire 5 minutes ago.
Through this collaboration, DRG and Zephyr Health will offer unique solutions that integrate provider, institution and payer data to bring rich, actionable insights to commercial teams. These solutions will enable life sciences sales and account teams to be at the forefront of understanding the most recent changes to payer or formulary status for their target markets and customers.
The partnership's first offering, "Market Access Potential" is a user-centric, analytics suite that leverages the new, advanced capabilities in the Zephyr Illuminate software platform as well as DRG's rich market access data. Market Access Potential will provide users real-time, relevant insights for improved account planning and customer engagement. This new platform will transform how market access data is managed within commercial teams, enabling a sales representative to understand physician access, formulary pull-through, and the increasing role of Integrated Delivery Networks (IDNs) and Accountable Care Organizations (ACOs) in physician decision making. Market Access Potential is currently enrolling charter customers and will be broadly available early in 2017.
Matthew McKnight, COO of DRG, commented, "As the healthcare access and reimbursement environment continues to evolve, DRG's partnership with Zephyr Health empowers life sciences companies by combining Zephyr's innovative software and intuitive design with proprietary data and analytics from DRG to provide a product that dramatically improves the efficiency and effectiveness of sales teams. By combining efforts, DRG and Zephyr Health have created a unique market access and reimbursement solution for the next wave of life science industry drug launches."
"We are excited to be working with DRG, an industry leader in market access data, to optimize how information is consumed by life sciences teams, and develop real-time recommendations for messaging and customer engagement," said Lance Scott, President and CEO, Zephyr Health. "Linking specific health plan information and providing visibility to the formulary and reimbursement status of a company's product at the individual physician level is a game-changer for commercial teams operating in a complicated and dynamic physician access landscape."
*About Decision Resources Group*
Decision Resources Group, a subsidiary of Piramal Enterprises Ltd., offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 1000 employees across 17 global locations. DRG provides the pharmaceutical, biotech, medical device, payer, provider, and financial services industries with the tools, insights and advice they need to compete and thrive in an increasingly complex and value-based marketplace.
DRG's Real World Data (RWD) repository covers over 260 million unique US patients with over five years of historical data. This robust claims data, combined with electronic health records (EHR) detail, allows for comprehensive analyses of in-market patient care, patient cost burden, and trends in patient outcomes. Additionally, DRG's RWD repository, integrated with leading formulary coverage analysis in the US, enables detailed profiling of health care provider prescribing and treatment behavior, and assists pharmaceutical and medical device manufacturers in identifying and eliminating barriers to patient access.
www.DecisionResourcesGroup.com
*About Zephyr Health*
Zephyr Health helps life sciences companies - pharmaceutical, biotech, medical device and diagnostics - engage the right physicians, accounts and institutions using insights from global health data. Zephyr Illuminate (TM) is a leading Insights-as-a-Service solution that integrates thousands of data sources to create precise and predictive insights. From pre-launch to product maturity, life sciences companies can make confident decisions faster with data-driven targeting and deep customer profiles. Zephyr Health's customers include several of the Top 10 Pharmaceutical, Biotech and Medical Device companies.
Zephyr Health is a privately held company headquartered in San Francisco with offices in London, UK, and Pune, India. Zephyr Health is venture backed by Google Ventures, Kleiner Perkins Caufield & Byers and Icon Ventures. For more information, please visit: www.zephyrhealth.com . Media contact for DRG:
Tori McClain
tmcclain@teamdrg.com
Media contact for Zephyr Health:
pr@zephyrhealth.com
--------------------This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zephyr Health via GlobeNewswire
HUG#2059943 Reported by GlobeNewswire 5 minutes ago.
↧
India beat England in 3rd Test, take 2-0 lead in series (Roundup)
Reported by newKerala.com 8 minutes ago.
↧
↧
Flipkart staring at Amazon's $5-bn challenge
Amazon has committed over $5 billion to grow its business in India so far and says it will pump in more capital as and when needed, a big worry for rival Flipkart which has been struggling to raise funds over the past couple of months.
Reported by Rediff.com 12 minutes ago.
↧
Jet Airways to start Wi-Fi on flights in India from March '17
Zee Media Bureau New Delhi: If flying in airplanes in the Indian airspace have any disadvantages, then inability to use phone or watching videos to remain entertained cab be counted as one of the major ones.
Reported by Zee News 6 minutes ago.
↧
People are against corruption, want progress, says PM Narendra Modi
"Over the last few days, we have seen the results of various polls -- parliamentary, assembly and civic polls -- across India," Prime Minister Narendra Modi said in a series of tweets.
Reported by Zee News 9 minutes ago.
↧
India should not mistake our patience for weakness: General Sharif
*Islamabad [Pakistan], Nov. 29 (ANI): Pakistan's outgoing Chief of Army Staff General Raheel Sharif said Tuesday that India should know that mistaking Pakistan's policy of patience for weakness would be dangerous.*
Reported by ANI News 6 minutes ago.
↧
↧
India E-commerce Logistics Market Overview: E-Tailing Market Has Grown from $0.64 Billion in 2013 to $4.6 Billion in 2015 Growing at a CAGR of 63% - Research and Markets
DUBLIN, Nov 29, 2016 /PRNewswire/ -- Research and Markets has announced the addition of the "India E-commerce Logistics Market Overview" report to their offering. Indian e-Commerce market has seen...
Reported by FinanzNachrichten.de 12 seconds ago.
↧
India hammer England to take 2-0 lead
Reported by Sify 4 minutes ago.
↧
Demonetisation a risky, but very brave decision by PM Modi, says Shivraj Chouhan
*Bhopal (Madhya Pradesh [India], Nov.29 (ANI): Madhya Pradesh Chief Minister Shivraj Singh Chouhan on Tuesday said that Prime Minister Narendra Modi's decision to demonetise the Rs.500 and Rs.1000 currency notes on November 8 this year was a risky but very brave one that would benefit the citizens of the country in the long term.*
Reported by ANI News 4 minutes ago.
↧
Rollback demonetisation or go back Modiji: Mamata Banerjee
[India], Nov. 29 (ANI): West Bengal Chief Minister Mamata Banerjee on Tuesday dubbed the demonetisation of high-value currency notes as 'black emergency' and said that the nation will very soon
Reported by Sify 3 minutes ago.
↧
↧
India's April-Oct fiscal deficit reaches 79.3 pct of full-year target
NEW DELHI, Nov 30 (Reuters) - India's fiscal deficit during the seven months to October was 4.24 trillion rupees ($61.91 billion), or 79.3 percent of the budgeted target for the fiscal year ending
Reported by Sify 54 minutes ago.
↧
Francis Cheka training hard before WBO title bout against Vijender Singh
[India], Nov.30 (ANI): Former world champion Francis Cheka is stepping up his training ahead of the big title defence bout against Indian boxing sensation Vijender Singh at the WBO Asia Pacific
Reported by Sify 53 minutes ago.
↧
RBI relaxes cash balance requirements for lenders
MUMBAI (Reuters) - The Reserve Bank of India (RBI) on Wednesday allowed lenders to include old 500 and 1,000 rupee notes as part of their cash balance, a move that analysts said would make it easier for the sector to fulfill their cash reserve ratio requirements.
Reported by Reuters India 2 minutes ago.
↧
Sport24.co.za | England call up Jennings for India tour
South Africa-born Keaton Jennings will join England for the remainder of their tour of India.
Reported by News24 46 minutes ago.
↧
↧
Takeda to Invest More Than 100 Million Euros in Dengue Vaccine Manufacturing Plant in Germany
*Business Wire India*Takeda Pharmaceutical Company Limited (TOKYO:4502) (“Takeda”) today announced that it will invest more than 100 Million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany. This represents a major step by Takeda toward meeting important unmet needs in dengue prevention. According to the World Health Organization (WHO), dengue is the fastest spreading mosquito-borne viral disease. Forty percent of the world’s population lives under the threat of the dengue virus, which causes an estimated 390 million infections and more than 20,000 deaths each year around the world in people of all ages. “This manufacturing plant investment reinforces Takeda’s strong support for our global vaccine strategy in general, and dengue in particular. The new plant will provide millions of people with access to a medicine that addresses a huge unmet medical need. It underlines our commitment to improve the lives of people worldwide,” says Dr. Thomas Wozniewski, Global Manufacturing & Supply Officer at Takeda. “Our colleagues in Singen have vast experience in lyophilisation technology, which is key for the manufacturing process of Takeda’s dengue vaccine finished product,” notes Thomas Wozniewski. Initial construction activities will start immediately, and the facility should be ready for production in 2019. On September 7, 2016 Takeda vaccinated the first subject in the Tetravalent Immunization against Dengue Efficacy Study (TIDES). TIDES is now enrolling approximately 20,000 healthy children between the ages of four and 16 years living in dengue-endemic countries in Latin America and Asia. The study is a Phase 3 double-blind, randomized, placebo-controlled trial of Takeda’s live-attenuated tetravalent dengue vaccine candidate. The study is evaluating the efficacy of the vaccine candidate to protect subjects against symptomatic dengue fever caused by any of the four dengue virus serotypes, regardless of age and whether the individual has previously been exposed to the virus. The study is also evaluating vaccine safety and immunogenicity, with two doses of the vaccine candidate or placebo administered 90 days apart. Dr. Rajeev Venkayya, President of Takeda Vaccines, adds “This dengue vaccine production facility is another strong indication of Takeda’s long-term commitment to vaccines. The progress of the dengue TIDES clinical trial, our partnership with the Bill & Melinda Gates Foundation to eradicate polio, the recent initiation of the world’s first field efficacy trial for a norovirus vaccine, and our work with the U.S. Government to develop a Zika vaccine, together demonstrate how Takeda is dedicated to developing and providing vaccines to protect people in need wherever they are.” *About the Dengue Vaccine Candidate (TAK-003)*Takeda’s tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus (DENV-2), which provides the genetic ‘backbone’ for all four vaccine viruses. Takeda’s dengue vaccine is being developed to support the protection of populations and individuals at risk for dengue across geographies whether or not they have had previous exposure to dengue virus, including: children and adults, travelers and those living in endemic areas. *About Takeda Pharmaceutical Company*
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.
Additional information about Takeda is available through its corporate website, www.takeda.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161129005575/en/ Reported by Business Wire India 30 minutes ago.
↧
JW Marriott Mumbai Sahar Bestowed with Several Prestigious Accolades
*Business Wire India*JW Marriott Mumbai Sahar awarded several prestigious awards in the year that’s gone by. The property has bagged the *‘Best Mice & Wedding Hotel’* at the *Hospitality India Awards 2016*, *‘Effective use of Marketing Communication Award’* at the* ‘Branding & Marketing Awards 2016’, Singapore*, and *‘Development of the year in Luxury and Upscale’* segment at the *Hotel Investment Forum India.*Mr. Saied Heidari, General Manager – JW Marriott Mumbai Sahar was awarded the *'Best General Manager - India' *at the *World Luxury Hotel Awards* besides being awarded the *‘Most Admired Hospitality Professional of 2016’*. Ms. Neesha Mohapatra, Director of Human Resources – JW Marriott Mumbai Sahar was awarded the *Women Super Achiever Award* and *HR Professional of the Year *at the *HR Tech Awards 2016 *held in Singapore.
Commenting on these accolades, *Mr. Saeid Heidari, General Manager at JW Marriott Mumbai Sahar* said, “It’s our continuous effort to provide our guests and clients with commendable hospitality services. The receiving of these awards perfectly resonate the same. In the coming here, we would strive harder to achieve greater results and continue to live up to our brand promise.”
*About JW Marriott Mumbai Sahar*
JW Marriott Mumbai Sahar opens doors to effortless elegance and sophistication. Located 1 km away from the Chhatrapati Shivaji International Airport Mumbai; making it an ideal destination for business and stay. With 585 intimate rooms, the property offers authentic cuisines crafted with passion, care and local flavours. With over 56,000 sq.ft. of indoor and outdoor convention space, the property offers 11 well-appointed meeting rooms with state-of-the-art conferencing facilities. The holistic Spa by JW offers a host of therapies to help you relax. At crafted perfectly so you are always left with the experience and luxury you truly desire.
Visit us online, http://www.marriott.com/hotels/travel/bomsa-jw-marriott-mumbai-sahar/, @jwsahar and www.facebook.com/JWSahar.
*About Marriott International*
*Marriott International, Inc.* (NASDAQ: MAR) is the world’s largest hotel company based in Bethesda, Maryland, USA, with nearly 6,000 properties in 120 countries and territories. Marriott operates and franchises hotels and licenses vacation ownership resorts. The company’s 30 leading brands include: Bulgari®, The Ritz-Carlton® and The Ritz-Carlton Reserve®, St. Regis®, W®, EDITION®, JW Marriott®, The Luxury Collection®, Marriott Hotels®, Westin®, Le Méridien®, Renaissance® Hotels, Sheraton®, Delta Hotels by MarriottSM, Marriott Executive Apartments®, Marriott Vacation Club®, Autograph Collection® Hotels, Tribute Portfolio™, Design Hotels™, Gaylord Hotels®, Courtyard®, Four Points® by Sheraton, SpringHill Suites®, Fairfield Inn & Suites®, Residence Inn®, TownePlace Suites®, AC Hotels by Marriott®, Aloft®, Element®, Moxy® Hotels, and Protea Hotels by Marriott®. The company also operates award-winning loyalty programs: Marriott Rewards®, which includes The Ritz-Carlton Rewards®, and Starwood Preferred Guest®. For more information, please visit our website at www.marriott.com, and for the latest company news, visit www.marriottnewscenter.com and @MarriottIntl.
*Photo Caption: *Team JWM Sahar with the Awards Reported by Business Wire India 44 minutes ago.
↧
Fiscal deficit in April-October at 79.3% of full year estimate
India's fiscal deficit during the seven months to October was Rs 4.24 trillion (USD 61.91 billion), or 79.3 percent of the budgeted target for the fiscal year ending in March 2017, government data showed on Wednesday.
Reported by Zee News 9 minutes ago.
↧
More Pages to Explore .....
